Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $7.5 million.

  • Lineage Cell Therapeutics' Operating Expenses fell 199.5% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.0 million, marking a year-over-year increase of 4745.94%. This contributed to the annual value of $31.0 million for FY2024, which is 802.01% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Operating Expenses stood at $7.5 million for Q3 2025, which was down 199.5% from $22.5 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Operating Expenses high stood at $29.2 million for Q4 2021, and its period low was $7.3 million during Q2 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' median Operating Expenses value was $8.1 million (recorded in 2024), while the average stood at $10.1 million.
  • In the last 5 years, Lineage Cell Therapeutics' Operating Expenses skyrocketed by 37692.31% in 2021 and then plummeted by 7105.68% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Operating Expenses stood at $29.2 million in 2021, then plummeted by 71.06% to $8.5 million in 2022, then decreased by 3.05% to $8.2 million in 2023, then fell by 2.64% to $8.0 million in 2024, then fell by 6.41% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $22.5 million for Q2 2025, and $8.0 million during Q1 2025.